|Bid||2.18 x 28000|
|Ask||2.42 x 1100|
|Day's Range||2.1700 - 2.3282|
|52 Week Range||1.2900 - 4.3400|
|Beta (3Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
The biotechnology sector really got hammered in 2018. In December the markets took many quality small cap biotechs down to historic low prices, observes Bill Mathews, small cap expert and editor of The Cheap Investor.
Bristol-Myers Squibb Co (NYSE: BMY) announced a deal to buy Celgene Corporation (NASDAQ: CELG) in a cash and stock transaction with an equity value of approximately $74 billion. Separately, the company announced FDA approval for an expanded indication for its Sprycel tablets to include the treatment of pediatric patients one year of age and older, with newly diagnosed Philadelphia chromosome-positive, or Ph+, acute lymphoblastic leukemia in combination with chemotherapy.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by disorders of the complement system, today announced that the Company’s Board of Directors has elected Nicole Vitullo Chair. Ms. Vitullo is a partner with Domain Associates LLC and has been a member of Achillion's Board of Directors since September 2010.
CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.
Achillion's (ACHN) shares rise following the announcement of positive interim data from early to mid-stage studies evaluating its factor D inhibitors ??? ACH-4471, ACH-5228 and ACH-5548.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Shares of Achillion Pharmaceuticals were in the red on Monday as traders waited for interim clinical-trial data from the company. Synergy Pharmaceuticals saw its shares explode on news from Cipher Pharmaceuticals Inc. announcing that its New Drug Submission for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide from Synergy earlier this year.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated disorders, today reported interim results for the Company’s Phase 2 trials of its first-generation oral factor D inhibitor, ACH-4471, as well as Phase 1 pharmacokinetics and potency data for its next-generation factor D inhibitors, ACH-5228 and ACH-5548. “These compelling findings underscore the momentum for Achillion and our factor D portfolio as we advance three oral small molecule compounds through clinical development.
Biotech stocks staged a modest comeback this week ending along with the broader market. The week saw a spate of clinical trial results releases , sending stocks moving in either direction. The tally of ...
Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. NASDAQ and Russell 2000 indices are already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in the first half of […]
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced today that the company will host a live webcast and conference call on December 17th at 4:30PM EST. Joseph Truitt, President and Chief Executive Officer and Dr. Stephen Zelenkofske, Executive Vice President and Chief Medical Officer will present Achillion’s 2019 development plans along with interim data for the Company’s Phase 2 clinical trials in PNH and C3G as well as initial Phase 1 data on Achillion’s next generation factor D inhibitors.
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary […]
On a per-share basis, the New Haven, Connecticut-based company said it had a loss of 12 cents. The company's shares closed at $2.95. A year ago, they were trading at $4. _____ This story was generated ...
If you’re interested in Achillion Pharmaceuticals Inc (NASDAQ:ACHN), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.